Role of Molecular Imaging using Ga-68 Somatostatin-Receptor PET/CT in Predicting Survival after Peptide Receptor Radionuclide Therapy of Neuroendocrine Neoplasms

#772

Introduction: Peptide receptor radionuclide therapy (PRRNT) is valuable for the management of metastasized and/or inoperable neuroendocrine neoplasms (NENs).

Aim(s): To evaluate the role of somatostatin receptor (SSTR) PET/CT using Ga-68 DOTATOC or DOTATATE in prediction of progression-free survival (PFS) and overall survival (OS) after PRRNT in patients with NENs.

Materials and methods: SSTR PET/CT was performed before, and 10 -14 weeks after each cycle of PRRNT (total n = 4) in 142 patients with progressive NENs (G1 and G2). Molecular response to PRRNT was evaluated according to the EORTC criteria. Patients were followed up for PFS and OS, which were correlated with molecular response as determined by SSTR PET/CT after 4th PRRNT cycle.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Kaemmerer D

Authors: Kulkarni H, Kaemmerer D, Hommann M, Hörsch D, Baum R,

Keywords: somatostatin receptor PET/CT, peptide receptor radionuclide therapy, survival,